Gene · 55
Papers3,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 3,704
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The miR-1185-2-3p-GOLPH3L pathway promotes glucose metabolism in breast cancer by stabilizing p53-induced SERPINE1. | J Exp Clin Cancer Res | 2021 | 33509226 | PubTator, text mining | PubMed |
| Exome-Wide Association Study Identifies FN3KRP and PGP as New Candidate Longevity Genes. | J Gerontol A Biol Sci Med Sci | 2021 | 33491046 | PubTator, text mining | PubMed |
| LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer. | J Oncol | 2021 | 33488712 | PubTator, text mining | PubMed |
| Adenine-Based Purines and Related Metabolizing Enzymes: Evidence for Their Impact on Tumor Extracellular Vesicle Activities. | Cells | 2021 | 33477811 | PubTator, text mining | PubMed |
| Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. | Cancers (Basel) | 2021 | 33477569 | PubTator, text mining | PubMed |
| Resistance to Antiandrogens in Prostate Cancer: Is It Inevitable, Intrinsic or Induced? | Cancers (Basel) | 2021 | 33477370 | PubTator, text mining | PubMed |
| The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. | Cancer Cell Int | 2021 | 33472628 | PubTator, text mining | PubMed |
| Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature. | PLoS One | 2021 | 33471819 | PubTator, text mining | PubMed |
| Comparative evaluation of two methods for LC-MS/MS proteomic analysis of formalin fixed and paraffin embedded tissues. | J Proteomics | 2021 | 33453434 | PubTator, text mining | PubMed |
| Mitochondrial Functionality in Male Fertility: From Spermatogenesis to Fertilization. | Antioxidants (Basel) | 2021 | 33445610 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review. | Int J Mol Sci | 2021 | 33440664 | PubTator, text mining | PubMed |
| Droplet-based mRNA sequencing of fixed and permeabilized cells by CLInt-seq allows for antigen-specific TCR cloning. | Proc Natl Acad Sci U S A | 2021 | 33431692 | PubTator, text mining | PubMed |
| Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. | Cancers (Basel) | 2021 | 33419051 | PubTator, text mining | PubMed |
| Comparison of Immunohistochemistry Expression of CK7, HMWK and PSA in High-Grade Prostatic Adenocarcinoma and Bladder Transitional Cell Carcinoma. | Iran J Pathol | 2021 | 33391378 | PubTator, text mining | PubMed |
| PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells. | Int J Biol Sci | 2021 | 33390843 | PubTator, text mining | PubMed |
| Predicting changes in renal metabolism after compound exposure with a genome-scale metabolic model. | Toxicol Appl Pharmacol | 2021 | 33387578 | PubTator, text mining | PubMed |
| Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. | Drugs | 2021 | 33369720 | PubTator, text mining | PubMed |
| Dendritic cell vaccine therapy for colorectal cancer. | Pharmacol Res | 2021 | 33348026 | PubTator, text mining | PubMed |
| Immune response drives outcomes in prostate cancer: implications for immunotherapy. | Mol Oncol | 2021 | 33338321 | PubTator, text mining | PubMed |
| Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: how the field developed and where we are now. | Purinergic Signal | 2021 | 33336318 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55/papers?page=31